Xanthine Oxidase Inhibition in Renal Transplant Recipients
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Cardiovascular Events
研究概览
简要总结
Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.
详细描述
This is a prospective, double-blind, placebo controlled, clinical trial examining vascular effects of allopurinol in patients who received a kidney transplant that are maintaining stable renal function for at least 1 year. End-points include pulse-wave velocity, systemic blood pressure and kidney function among others.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age 18 years or older
- •both genders
- •recipients of living donor or deceased-donor kidney transplant with stable renal function
排除标准
- •history of gout
- •allergy to allopurinol
- •use of azathioprine
研究组 & 干预措施
Allopurinol
干预措施: allopurinol or placebo (Drug)
Placebo (sugar pill)
干预措施: Placebo (Other)
结局指标
主要结局
Cardiovascular Events
时间窗: 3 years
Number of major cardiovascular events
Endothelial Function
时间窗: 3 years
Changes in flow-mediated dilatation of braquial artery.
次要结局
- Arterial Stiffness(3 years)
研究者
Roberto S Kalil
Clinical Professor of Medicine
University of Iowa